Macrophage CD14 impacts immune defenses against influenza virus in allergic hosts.
Fungal asthma
Inflammation
Mouse
Journal
Microbial pathogenesis
ISSN: 1096-1208
Titre abrégé: Microb Pathog
Pays: England
ID NLM: 8606191
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
09
08
2018
revised:
15
10
2018
accepted:
04
12
2018
pubmed:
12
12
2018
medline:
15
3
2019
entrez:
12
12
2018
Statut:
ppublish
Résumé
Asthma and influenza are leading causes of worldwide morbidity and mortality. Although these two conditions can co-exist in the same patient, the immune parameters that impact disease outcomes are not fully elucidated. The importance of macrophages to both conditions suggested a role for CD14, a co-receptor for endotoxin, as a regulatory mechanism for innate immune responses during asthma and influenza co-morbidity. Herein, we hypothesized that parameters of influenza morbidity will be reduced in the absence of CD14. Age and gender matched wild-type (WT) and CD14 knock-out (KO) mice were subjected to our validated model of Aspergillus-induced model of asthma and/or influenza. Characteristics of disease pathogenesis were investigated using standard methods in weight loss, flow cytometry, airway resistance, histology, quantitative real-time PCR, and viral titer quantification. The absence of CD14 did not have an impact on morbidity as these mice were equally susceptible to disease with similar airway resistance. Peribronchovascular inflammation and goblet cell content were equivalent between WT and KO mice in asthma alone and asthma and influenza co-morbidity. Co-morbid KO mice had less lymphocytes and eosinophils in the airways although their lung viral burden was equivalent to WT. Inflammatory gene signatures were altered in co-morbid mice in each genotype. CD14 expression on macrophages is necessary for airway inflammation but not for viral pathogenesis in allergic hosts.
Identifiants
pubmed: 30529429
pii: S0882-4010(18)31405-0
doi: 10.1016/j.micpath.2018.12.008
pmc: PMC7872093
mid: NIHMS1662869
pii:
doi:
Substances chimiques
Lipopolysaccharide Receptors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
212-219Subventions
Organisme : NIAID NIH HHS
ID : R01 AI125481
Pays : United States
Informations de copyright
Published by Elsevier Ltd.
Références
Proc Am Thorac Soc. 2007 Jul;4(3):221-5
pubmed: 17607003
J Clin Invest. 1996 Mar 15;97(6):1398-408
pubmed: 8617871
Am J Respir Cell Mol Biol. 2006 May;34(5):527-36
pubmed: 16415249
J Immunol. 2017 Apr 15;198(8):3214-3226
pubmed: 28283567
Immunity. 2000 Oct;13(4):443-51
pubmed: 11070163
Immunobiology. 2004;209(1-2):3-10
pubmed: 15481135
Science. 2004 May 14;304(5673):1014-8
pubmed: 15143282
Nature. 2011 Feb 24;470(7335):543-7
pubmed: 21350488
Infect Immun. 2014 Aug;82(8):3240-51
pubmed: 24866794
BMC Cancer. 2012 Jan 19;12:26
pubmed: 22260435
Eur J Immunol. 2006 Jun;36(6):1364-73
pubmed: 16703568
Mucosal Immunol. 2010 Jan;3(1):29-39
pubmed: 19865078
Am J Respir Crit Care Med. 2001 Mar;163(4):965-9
pubmed: 11282774
Peptides. 2010 Jun;31(6):1068-75
pubmed: 20226823
Cell. 2008 Apr 18;133(2):235-49
pubmed: 18423196
Eur Respir J. 2008 Jan;31(1):143-78
pubmed: 18166595
Nature. 2013 May 23;497(7450):498-502
pubmed: 23636320
J Leukoc Biol. 2012 Aug;92(2):319-24
pubmed: 22591690
J Immunol. 1998 Jul 15;161(2):919-26
pubmed: 9670970
Immunology. 2004 Oct;113(2):175-7
pubmed: 15379977
J Exp Med. 1987 Jan 1;165(1):64-9
pubmed: 3794607
Nat Commun. 2015 Feb 17;6:6281
pubmed: 25687754
Immunol Cell Biol. 2014 May-Jun;92(5):449-59
pubmed: 24469764
Nat Rev Immunol. 2003 Jan;3(1):23-35
pubmed: 12511873
Nat Immunol. 2000 Nov;1(5):398-401
pubmed: 11062499
J Immunol. 2002 May 1;168(9):4524-30
pubmed: 11970998
Annu Rev Physiol. 2017 Feb 10;79:541-566
pubmed: 27813830
Antiviral Res. 2016 Sep;133:208-17
pubmed: 27531368
FASEB J. 2004 Jun;18(9):995-7
pubmed: 15059974
J Immunol. 2013 Aug 1;191(3):1250-9
pubmed: 23804714
Am J Respir Cell Mol Biol. 1999 May;20(5):976-83
pubmed: 10226067
Int J Clin Exp Med. 2015 Aug 15;8(8):13830-5
pubmed: 26550333
Med Mycol. 2010 Dec;48(8):1056-65
pubmed: 20482452
Immunobiology. 2017 Dec;222(12):1064-1073
pubmed: 28889999
Sci Rep. 2018 May 4;8(1):7061
pubmed: 29728628
J Biol Chem. 2008 Sep 5;283(36):24748-59
pubmed: 18559343
Nat Immunol. 2002 Apr;3(4):347-53
pubmed: 11887181
Am J Respir Cell Mol Biol. 2012 May;46(5):703-13
pubmed: 22246861
PLoS One. 2010 Oct 01;5(10):
pubmed: 20957211
Microbiol Immunol. 2010 Sep;54(9):558-63
pubmed: 20840155
Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2281-6
pubmed: 11854525
N Engl J Med. 2009 Nov 12;361(20):1935-44
pubmed: 19815859
Lancet. 2018 Feb 24;391(10122):783-800
pubmed: 29273246
Nat Genet. 2000 Jun;25(2):187-91
pubmed: 10835634
Eur Respir J. 2016 Oct;48(4):1201-1214
pubmed: 27587549
EMBO J. 2000 Aug 1;19(15):4046-55
pubmed: 10921885
Lab Invest. 2012 Jun;92(6):937-48
pubmed: 22391959
FEBS Lett. 1996 Jan 8;378(2):126-30
pubmed: 8549817
J Allergy Clin Immunol. 2008 Dec;122(6):1200-1207.e1
pubmed: 19084112
Nature. 2014 Jan 16;505(7483):412-6
pubmed: 24317696
Infect Immun. 2009 May;77(5):2184-92
pubmed: 19204090
Circulation. 1999 Jun 29;99(25):3218-20
pubmed: 10385492
Science. 1998 Dec 11;282(5396):2085-8
pubmed: 9851930
J Biol Chem. 2002 Oct 18;277(42):39320-6
pubmed: 12171914
Front Immunol. 2018 Aug 10;9:1843
pubmed: 30147697
Circulation. 1995 Sep 15;92(6):1565-9
pubmed: 7664441
Multidiscip Respir Med. 2016 Oct 12;11:37
pubmed: 27752310